VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Jul 10, 2007 -- bioLytical Laboratories (bioLytical) announced today the U.S. Food and Drug Administration (FDA) has accepted the Investigational Device Exemption (IDE) application for INSTI(TM), a 60-second rapid HIV test for point-of-care testing. The acceptance clears the way for bioLytical to immediately begin its US clinical trials.
